Zoetis Inc. Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit

Radnor, Pennsylvania – July 15, 2026 – Kessler Topaz Meltzer & Check, LLP, a nationally recognized securities litigation firm, informs investors that a securities fraud class action lawsuit has been filed against Zoetis Inc. (Zoetis) (NYSE: ZTS). The lawsuit is brought on behalf of investors who purchased or acquired Zoetis securities between January 14, 2025, and May 6, 2026. Investors have until July 27, 2026, to seek lead plaintiff status.

The complaint, filed in the U.S. District Court for the Southern District of New York, alleges that Zoetis made materially false or misleading statements and failed to disclose material facts. Specifically, the suit claims that prescription growth and adoption of Librela, a canine pain treatment, weakened following FDA safety warnings about neurological complications. It also alleges that Simparica Trio, a flea, tick, and heartworm preventative, lost significant market share to a lower-priced competitor, as did the dermatological products Apoquel and Cytopoint.

Zoetis's stock price fell 21.5% on May 7, 2026, after the company reported first-quarter 2026 financial results showing a significant decline in its Companion Animal business. Investors who purchased Zoetis securities during the Class Period and suffered losses are encouraged to contact Kessler Topaz Meltzer & Check, LLP.

Investors may opt out of the class by taking no action, and they will remain absent class members. The lead plaintiff role involves directing the litigation and selecting counsel to represent the class. Any investor who meets the criteria and has suffered losses is invited to contact the firm for a free case evaluation.